Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?
(1993) In Immunology Today 14(10). p.477-479- Abstract
Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/39816fd2-df09-4b86-bc02-a4e8bda83eff
- author
- Borrebaeck, Carl A K LU ; Malmborg, Ann-Christin LU and Ohlin, Mats LU
- organization
- publishing date
- 1993
- type
- Contribution to journal
- publication status
- published
- in
- Immunology Today
- volume
- 14
- issue
- 10
- pages
- 3 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:8274187
- scopus:0027485672
- ISSN
- 0167-5699
- DOI
- 10.1016/0167-5699(93)90259-N
- language
- English
- LU publication?
- yes
- id
- 39816fd2-df09-4b86-bc02-a4e8bda83eff
- date added to LUP
- 2016-04-20 13:45:23
- date last changed
- 2024-01-04 02:31:56
@article{39816fd2-df09-4b86-bc02-a4e8bda83eff, abstract = {{<p>Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.</p>}}, author = {{Borrebaeck, Carl A K and Malmborg, Ann-Christin and Ohlin, Mats}}, issn = {{0167-5699}}, language = {{eng}}, number = {{10}}, pages = {{477--479}}, publisher = {{Elsevier}}, series = {{Immunology Today}}, title = {{Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?}}, url = {{http://dx.doi.org/10.1016/0167-5699(93)90259-N}}, doi = {{10.1016/0167-5699(93)90259-N}}, volume = {{14}}, year = {{1993}}, }